Diagnosis and management of prefibrotic myelofibrosis

Area of Science:

• Hematology
• Oncology
• Myeloproliferative Neoplasms

Background:

• The 2016 WHO classification distinguishes early/prefibrotic primary myelofibrosis (pre-PMF) from overt fibrotic PMF.
• Accurate differentiation from essential thrombocythemia (ET) is crucial due to differing clinical outcomes and disease progression.
• Pre-PMF presents unique challenges in diagnosis and management.

Purpose of the Study:

• To provide an overview of diagnosing and stratifying patients with pre-PMF.
• To highlight the specific risks associated with pre-PMF, including vascular events and disease evolution.
• To guide individualized counseling and management strategies for pre-PMF patients.

Main Methods:

• Review of diagnostic criteria based on bone marrow morphology and fibrosis grade.
• Analysis of clinical features including leukoerythroblastosis, anemia, leukocytosis, LDH levels, and splenomegaly.
• Comparison of pre-PMF with overt PMF and essential thrombocythemia (ET).

Main Results:

• Pre-PMF is characterized by fibrosis grades 0-1.
• Patients with pre-PMF face risks of vascular events and disease progression, similar to overt PMF.
• Pre-PMF exhibits a distinct clinical course compared to overt PMF.

Conclusions:

• Pre-PMF requires careful diagnosis and risk stratification due to its unique risk profile.
• Management strategies should consider both thrombo-hemorrhagic risks and potential for disease evolution.
• Individualized patient counseling is essential for optimal care in pre-PMF.